Overview
The HHS Office of the Inspector General’s (OIG) trend of Anti-Kickback Statute (AKS) enforcement proceedings against medical products companies has continued in the past several years. Yet, some recent OIG advisory opinions have found that OIG would not impose administrative sanctions for certain financial arrangements under the AKS. During this webinar, we will discuss recent trends in AKS enforcement as well as safe harbors. We will cover how to comply with AKS requirements, including government expectations and requirements, investigative best practices, self-disclosure, and privilege issues.
Internet Explorer and Microsoft Edge are not supported by the checkout process.
Please use Chrome, Firefox, or Safari. If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.
Speakers
John Bentivoglio, Partner, Skadden, Arps, Slate, Meagher & Flom LLP
Hannah Bornstein, Partner, Nixon Peabody LLP
Lisa Rachlin, Commercial Counsel, Vertex Pharmaceuticals, Inc.
Jennifer Schwartz, Managing Counsel, Office of the General Counsel, Merck & Co., Inc.
Virtual Learning FAQ
Related Content